(12E)-(7S,9R,10S)-4,9-bis-(tert-butyldimethylsilyloxy)-7-[(2E)-3-carboxyprop-2-enyl]-10-methyl-7,8,9,10,11,14-hexahydro-6-oxa-benzocyclodecen-5-one | 320573-60-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: (12E)-(7S,9R,10S)-4,9-bis-(tert-butyldimethylsilyloxy)-7-[(2E)-3-carboxyprop-2-enyl]-10-methyl-7,8,9,10,11,14-hexahydro-6-oxa-benzocyclodecen-5-one
• 英文别名: (E)-4-[(4S,6R,7S,9E)-6,16-bis[[tert-butyl(dimethyl)silyl]oxy]-7-methyl-2-oxo-3-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraen-4-yl]but-2-enoic acid
• CAS: 320573-60-2
• 化学式: C₃₂H₅₂O₆Si₂
• 分子量: 588.932
• InChiKey: JYIFPAWOHPQJTG-ROCJPGLESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.55
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  82.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (12E)-(7S,9R,10S)-4,9-bis-(tert-butyldimethylsilyloxy)-7-[(2E)-3-carboxyprop-2-enyl]-10-methyl-7,8,9,10,11,14-hexahydro-6-oxa-benzocyclodecen-5-one 在 sodium azide 、 N,N-二异丙基乙胺 作用下， 以 水 、 丙酮 、 甲苯 为溶剂， 反应 0.75h， 生成 (4S,6R,7S,9E)-6,16-bis[[tert-butyl(dimethyl)silyl]oxy]-4-[(E)-3-isocyanatoprop-2-enyl]-7-methyl-3-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraen-2-one
  参考文献：
  名称：

  （-）-水杨酰卤酰胺A及其相关同系物的全合成

  摘要：

  一个新的海洋海绵代谢产物（-）-水杨酰卤酰胺A（1）的简明高效的全合成方法已经实现。的合成策略的主要功能包括一个高度Ë -选择性闭环复分解来构造12元salicylihalamide甲大环化合物和用于安装的不稳定的烯七- （的实用方法Ž，Ž）-dienamide侧链涉及ñ -依恩卡巴特5的酰化，后者通过酰基叠氮化物的形成和库尔图斯热重排衍生自相应的α，β-不饱和羧酸28。两个结构简化的类似物（3和4还制备了对多种人肿瘤细胞系表现出显着但减弱的细胞生长抑制活性的C1-C12细胞。

  DOI：

  10.1016/s0040-4020(02)00657-9
• 作为产物：
  描述：

  2-羟基-6-甲基苯甲酸 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 tris-(dibenzylideneacetone)dipalladium(0) 2,6-二甲基吡啶 、 4-二甲氨基吡啶 、 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 三(2-呋喃基)膦 、 sodium hydride 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 四氯化碳 、 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 113.0h， 生成 (12E)-(7S,9R,10S)-4,9-bis-(tert-butyldimethylsilyloxy)-7-[(2E)-3-carboxyprop-2-enyl]-10-methyl-7,8,9,10,11,14-hexahydro-6-oxa-benzocyclodecen-5-one
  参考文献：
  名称：

  Formal Total Synthesis of Salicylihalamides A and B

  摘要：

  An efficient synthesis of the macrolactone 3 of the salicylihalamides in 10 linear steps from alkene 6 is described. The key steps involved a Stille coupling between the chiral stannane 5 and benzyl bromide 4, which produced alkene 15 in good yield, and subsequent base-induced macrolactonization then gave compound 3. Macrolactone 3 was then converted into the known salicylihalamide A intermediate 18 in a three-step sequence. Compound 3 was also converted into another known salicylihalamide A and B intermediate 23 in a five-step sequence.

  DOI：

  10.1021/jo026798h

文献信息

• Total Synthesis and Initial Structure−Function Analysis of the Potent V-ATPase Inhibitors Salicylihalamide A and Related Compounds
  作者：Yusheng Wu、Xibin Liao、Ruifang Wang、Xiao-Song Xie、Jef K. De Brabander

  DOI：10.1021/ja0177713

  日期：2002.4.1

  products that induce a variety of interesting phenotypes in cultured mammalian cells. Salicylihalamide A was reported to be a unique and highly differential cytotoxin and a potent inhibitor of the mammalian vacuolar (H(+))-ATPase. The total synthesis of both enantiomers of salicylihalamide A, a revision of the absolute configuration assigned to the natural product, and extensive structure-function studies

  Salicylihalamide A 是不断增长的一类大环水杨酸盐天然产物的第一个成员，这些产物在培养的哺乳动物细胞中诱导各种有趣的表型。据报道，Salicylihalamide A 是一种独特且高度差异化的细胞毒素，是哺乳动物液泡 (H(+))-ATPase 的有效抑制剂。报告了水杨酰卤 A 的两种对映异构体的全合成、分配给天然产物的绝对构型的修订以及与合成水杨酰卤变体的广泛结构-功能研究。这些研究之所以成为可能，仅是由于一种高效的合成策略，该策略具有以下特点：（1）显着的 E 选择性闭环烯烃复分解反应以构建 12 元苯内酯骨架 29，（2）对 E-烯基异氰酸酯进行温和的立体控制加工 41 , (3) 添加碳，氧和硫亲核试剂生成异氰酸酯 41，得到水杨酰卤酰胺 A 和同系物。我们首次证明水杨酰胺 A 是来自牛脑的完全纯化的重组 V-ATP 酶的有效抑制剂，并且已经确定了几种类似有效的侧链修饰衍生物，包括水杨酰胺二聚体
• Total Synthesis of (−)-Salicylihalamide A
  作者：Barry B. Snider、Fengbin Song

  DOI：10.1021/ol015822v

  日期：2001.6.1

  [GRAPHICS]A 16-step synthesis of the novel cytotoxin salicylihalamide A (1E) has been achieved in 3.3% overall yield using ring closing metathesis to generate the macrolide and addition of (1Z,3Z)-hexadienylcuprate (2), which was generated in situ from ethylcuprate and acetylene, to alkenyl isocyanate 3 to form the side chain.
• Synthesis and Initial Structure−Activity Relationships of Modified Salicylihalamides
  作者：Yusheng Wu、Olga R. Seguil、Jef K. De Brabander

  DOI：10.1021/ol0068086

  日期：2000.12.1

  [GRAPHICS]The first stereoselective total synthesis of the potent antitumor compound (-)-salicylihalamide A is presented. The practicality of our approach provides for high material throughput and is highlighted by the rapid construction of a variety of modified congeners. Initial structure-activity relationships are derived from growth inhibition experiments with a human melanoma cancer cell line.
• Total synthesis of (−)-salicylihalamide A and related congeners
  作者：Amos B Smith、Junying Zheng

  DOI：10.1016/s0040-4020(02)00657-9

  日期：2002.8

  A concise, highly efficient total synthesis of (−)-salicylihalamide A (1), a novel marine sponge metabolite, has been achieved. Key features of the synthetic strategy include a highly E-selective ring-closing metathesis to construct the 12-membered salicylihalamide A macrocycle and a practical method for installation of the labile ene-hepta-(Z,Z)-dienamide side chain involving N-acylation of enecabarmate

  一个新的海洋海绵代谢产物（-）-水杨酰卤酰胺A（1）的简明高效的全合成方法已经实现。的合成策略的主要功能包括一个高度Ë -选择性闭环复分解来构造12元salicylihalamide甲大环化合物和用于安装的不稳定的烯七- （的实用方法Ž，Ž）-dienamide侧链涉及ñ -依恩卡巴特5的酰化，后者通过酰基叠氮化物的形成和库尔图斯热重排衍生自相应的α，β-不饱和羧酸28。两个结构简化的类似物（3和4还制备了对多种人肿瘤细胞系表现出显着但减弱的细胞生长抑制活性的C1-C12细胞。
• Formal Total Synthesis of Salicylihalamides A and B
  作者：Georgina A. Holloway、Helmut M. Hügel、Mark A. Rizzacasa

  DOI：10.1021/jo026798h

  日期：2003.3.1

  An efficient synthesis of the macrolactone 3 of the salicylihalamides in 10 linear steps from alkene 6 is described. The key steps involved a Stille coupling between the chiral stannane 5 and benzyl bromide 4, which produced alkene 15 in good yield, and subsequent base-induced macrolactonization then gave compound 3. Macrolactone 3 was then converted into the known salicylihalamide A intermediate 18 in a three-step sequence. Compound 3 was also converted into another known salicylihalamide A and B intermediate 23 in a five-step sequence.